Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting State
Conditions
Fasting State
Trial Timeline
Apr 1, 2011 → Nov 1, 2011
NCT ID
NCT01603173About Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate
Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate is a phase 1 stage product being developed by Ipca Laboratories for Fasting State. The current trial status is completed. This product is registered under clinical trial identifier NCT01603173. Target conditions include Fasting State.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01603173 | Phase 1 | Completed |
| NCT01603186 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting State
Other Products from Ipca Laboratories
Metoprolol Succinate ER Tablets 50 mg + 'TOPROL-XL®' ER Tablets 50 mgPhase 1
33
Indomethacin Extended-Release Capsules USP 75 mg + Indomethacin Extended Release Capsules USP 75 mgPhase 1
33
Ondansetron Tablets USP 8 mg + Ondansetron HydrochloridePhase 1
33
Etodolac Capsules USP 300 mg + EtodolacPhase 1
33
Risperidone Tablet 1 mg + RisperidonePhase 1
33